Table 2.
Current clinical trials testing AXL-targeted agents in GI cancer patients.
| Intervention | Primary target | Condition | Co-treatment/comparator | Clinical trial | Identifier |
|---|---|---|---|---|---|
| BGB324 | Inhibitor of AXL kinase | Pancreatic cancer | Nab-paclitaxel Gemcitabine Cisplatin |
Phase 1 Phase 2 |
NCT03649321 |
| AVB-500 | AXL decoy soluble receptor, binds GAS6 | Phase 1 Safety and Tolerability Study |
Placebo | Phase 1 | NCT03401528 |
| AVB-500 | AXL decoy soluble receptor, binds GAS6 | Pancreatic Adenocarcinoma | Nab paclitaxel Gemcitabine |
Phase 1 Phase 2 |
NCT04983407 |
| BA3011 | Conditionally active biologic anti-AXL antibody drug conjugate | Advanced Solid Tumor (Phase 1) Solid Tumor |
PD-1 inhibitor | Phase 1 Phase 2 |
NCT03425279 |
| Cabozantinib | Small molecule inhibitor of multiple receptor tyrosine kinases including MET, VEGFR 1, 2 and 3, AXL, and RET | Gastric Cancer Esophageal Adenocarcinoma Hepatocellular Carcinoma Colorectal Cancer |
Durvalumab anti-(Programmed cell death protein 1 (PD-L1) inhibitor Tremelimumab |
Phase 1 Phase 2 |
NCT03539822 |
| Cabozantinib | Hepatocellular Carcinoma | Placebo | Phase 3 | NCT01908426 | |
| Cabozantinib | Hepatocellular Carcinoma | Phase 2 | NCT04316182 | ||
| Cabozantinib | Hepatocellular Carcinoma Recurrent Cancer Liver Transplant |
Phase 2 | NCT04204850 | ||
| Cabozantinib | Hepatocellular Carcinoma | Sorafenib Atezolizumab |
Phase 3 | NCT03755791 | |
| Cabozantinib | Malignant Solid Tumor | Phase 2 | NCT04116541 | ||
| SLC-391 | Inhibitor of AXL | Solid Tumor | Phase 1 | NCT03990454 | |
| TP-0903 | Inhibitor of AXL | Advanced Solid Tumors EGFR Positive Non-small Cell Lung Cancer Colorectal Carcinoma Recurrent Ovarian Carcinoma BRAF-Mutated Melanoma |
Phase 1 | NCT02608268 | |
| Warfarin | Inhibits AXL activation, Vitamin K agonist | Pancreatic Cancer | Withdrawn | NCT03536208 | |
| MGCD516 | c-Kit, PDGFRα/β, TAM, VEGF | Advanced Cancer | Phase 1 | NCT02219711 | |
| BPI-9016M | Inhibitor of MET/AXL kinases. | Solid tumors | Phase 1 | NCT02478866 | |
| Crizotinib | a small molecule directed to vascular endothelial growth factor receptors, MET and AXL | Hematologic Cancers Solid Tumors Metastatic Cancer |
Phase 2 | NCT02034981 | |
| INCB081776 | Inhibitor of AXL and Mer that blocks TAM | Advanced Solid Tumors | INCMGA00012 | Phase 1 | NCT03522142 |